Scholarlink

<p>Introduction. <i>Bifidobacterium breve</i> species have demonstrated potential therapeutic effects on acute diarrhea; however, supporting clinical evidence remains limited. This study evaluates the impact of a combination of <i>Bifidobacterium breve</i> BR03 and <i>Bifidobacterium breve</i> B632 on the clinical outcomes of children with acute diarrhea. Methods. This randomized, prospective study included children aged six months to five years at a tertiary care center. The intervention group received a probiotic formulation containing <i>B. breve</i> BR03 and <i>B. breve</i> B632 (five drops/day) alongside peroral zinc (15 mg/day) and oral rehydration solution (ORS) for five days. The control group received ORS and peroral zinc for the same duration. Results. Among the 120 enrolled children, 72 (60%) were boys. The median ages were 32.0 months (18.0–45.0) in the study group and 30.0 months (17.0–55.0) in the control group, with no significant differences in baseline characteristics. Stool frequency was significantly lower in the study group at 24–48 h (2.41 ± 1.99 vs. 3.07 ± 1.71, <i>p</i> = 0.020), 48–72 h (0.98 ± 1.31 vs. 1.90 ± 1.58, <i>p</i> &lt; 0.001), and 72–96 h (0.44 ± 1.18 vs. 1.03 ± 1.35, <i>p</i> &lt; 0.001). The proportion of children experiencing diarrhea at these intervals was also significantly lower in the probiotic group. Conclusion. The combination of <i>B. breve</i> BR03 and <i>B. breve</i> B632 significantly reduces stool frequency and diarrhea duration in children with acute diarrhea, supporting its potential as an adjunct therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The beneficial effect of Bifidobacterium breve Br03 and Bifidobacterium breve B632 mixture in acute infectious diarrhea in children

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月25日

查看全文
  • Soner Sertan Kara,
  • Kartal Berkay Gürkan,
  • Eda Somuncu,
  • İlknur Çağlar

摘要

Introduction. Bifidobacterium breve species have demonstrated potential therapeutic effects on acute diarrhea; however, supporting clinical evidence remains limited. This study evaluates the impact of a combination of Bifidobacterium breve BR03 and Bifidobacterium breve B632 on the clinical outcomes of children with acute diarrhea. Methods. This randomized, prospective study included children aged six months to five years at a tertiary care center. The intervention group received a probiotic formulation containing B. breve BR03 and B. breve B632 (five drops/day) alongside peroral zinc (15 mg/day) and oral rehydration solution (ORS) for five days. The control group received ORS and peroral zinc for the same duration. Results. Among the 120 enrolled children, 72 (60%) were boys. The median ages were 32.0 months (18.0–45.0) in the study group and 30.0 months (17.0–55.0) in the control group, with no significant differences in baseline characteristics. Stool frequency was significantly lower in the study group at 24–48 h (2.41 ± 1.99 vs. 3.07 ± 1.71, p = 0.020), 48–72 h (0.98 ± 1.31 vs. 1.90 ± 1.58, p < 0.001), and 72–96 h (0.44 ± 1.18 vs. 1.03 ± 1.35, p < 0.001). The proportion of children experiencing diarrhea at these intervals was also significantly lower in the probiotic group. Conclusion. The combination of B. breve BR03 and B. breve B632 significantly reduces stool frequency and diarrhea duration in children with acute diarrhea, supporting its potential as an adjunct therapy.